Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency.

Authors：Ikoma Naruhiko; Cloyd Jordan; Badgwell Brian D; Agnes Annamaria; Rodriguez Bigas Miguel; Ajani Jaffer A; You Y Nancy

Source：Journal of Surgical Oncology, 2017.

DOI：10.1002/jso.24926

• DNA mismatch repair deficiency
• chemotherapy
• gastric cancer
• surgery
• survival

Patients with germline DNA mismatch repair deficiency (dMMR) have an increased risk of gastric cancer. From our institutional database, we identified 12 patients with germline dMMR gastric cancer. Ten patients (83%) underwent surgical resection, with a 5-year overall survival rate of 88%. None of the three patients who received preoperative therapy and five patients with recurrent or metastatic disease experienced a significant response to 5-fluorouracil-based chemotherapy.

• Institution
  The University of Texas, MD Anderson Cancer Center; the university of Texas MD Anderson Cancer Center; University of Texas M.D.Anderson Cancer Center; University of Texas M.D.Anderson cancer center; University of Texas,M.D.Anderson Cancer Center; University Of Texas MD Anderson Cancer Center; The university of Texas,M.D.Anderson Cancer Center